Background
Methods
Subjects
Data collection
Variables
Statistical analysis
Results
Patient characteristics
Variables | Cardiovascular outcomes of interest | p-value | ||
---|---|---|---|---|
Total N = 1169 | CVD N = 148 | No CVD N = 1013 | ||
Female sex, n (%) | 609 (53.3%) | 57 (38.5%) | 550 (55.7%) | < 0.001 |
Age (years), mean (± SD) | 40.0 (± 16.7) | 58.5 (± 13.7) | 37.3 (± 15.4) | < 0.001 |
Age (years), median (IQR) | 37.0 (24.9-52.0) | 59.0 (49.0-68.2) | 33.8 (23.9-47.2) | < 0.001 |
Diabetes duration (years), mean (SD) | 19.2 (± 14.4) | 34.8 (± 15.5) | 17.1 (± 12.8) | < 0.001 |
Diabetes duration (years), median (IQR) | 16.0 (8.0-27.0) | 35.0 (24.5-45.0) | 15.0 (8.0-24.0) | < 0.001 |
Diabetes duration (≥ 20.0 years), n (%) | 476 (41.3%) | 121 (84.0%) | 354 (35.4%) | < 0.001 |
HbA1c (%), mean (± SD) | 8.5 (± 1.8) | 8.6 (± 1.5) | 8.5 (± 1.9) | 0.386 |
HDL-Ca, mean (± SD) | 1.53 (± 0.54) | 1.35 (± 0.42) | 1.56 (± 0.56) | < 0.001 |
LDL-Ca, mean (± SD) | 2.55 (± 0.95) | 2.15 (± 0.82) | 2.62 (± 0.95) | < 0.001 |
Total-Ca, mean (± SD) | 4.73 (± 1.09) | 4.18 (± 1.12) | 4.83 (± 1.06) | < 0.001 |
Triglyceridesa, mean (± SD) | 1.37 (± 1.42) | 1.54 (± 1.84) | 1.34 (± 1.34) | 0.190 |
Systolic BPb, mean (± SD) | 124 (± 17) | 132 (± 21) | 123 (± 16) | < 0.001 |
Diastolic BPb, mean (± SD) | 74 (± 10) | 72 (± 10) | 74 (± 10) | 0.073 |
BMI categories, n (%) (kg/m2) | 0.372 | |||
< 18.5 | 20 (2.0%) | 4 (3.2%) | 15 (1.7%) | |
18.5 to < 25 | 419 (41.6%) | 51 (40.5%) | 365 (41.8%) | |
25 to < 30 | 315 (31.3%) | 34 (27.0%) | 279 (31.9%) | |
≥ 30 | 253 (25.1%) | 37 (29.4%) | 215 (24.6%) | |
Ever smoked, n (%) | 397 (38.5%) | 86 (64.2%) | 309 (34.6%) | < 0.001 |
Albuminuria, n (%) | 220 (31.1%) | 46 (47.9%) | 174 (28.6%) | < 0.001 |
eGFRc, mean (± SD) | 97 (± 28) | 71 (± 29) | 101 (± 25) | < 0.001 |
Antihypertensive Rx, n (%) | 320 (28.1%) | 105 (72.9%) | 214 (21.7%) | < 0.001 |
Lipid lowering Rx, n (%) | 342 (29.7%) | 110 (75.3%) | 232 (23.2%) | < 0.001 |
Retinopathy, n (%) | 284 (24.7%) | 82 (56.2%) | 202 (20.2%) | < 0.001 |
Cardiovascular complications
Variables | Univariable analyses | Multivariable analyses | ||||
---|---|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | ROC | 95% CI | |
Cardiovascular disease (composite) | ||||||
Female sex | 0.50 (0.35–0.71) | < 0.001 | 0.90 (0.46–1.78) | 0.764 | 0.88 | 0.84–0.92 |
Age (years) | 1.08 (1.07–1.09) | < 0.001 | 1.06 (1.03–1.09) | < 0.001 | ||
Diabetes duration group | 1.12 (1.09–1.15) | < 0.001 | 1.05 (1.01–1.10) | 0.018 | ||
HbA1c (%) | 1.04 (0.95–1.15) | 0.386 | ||||
HDL-cholesterol (mmol/L) | 0.36 (0.21–0.62) | < 0.001 | 0.43 (0.21–0.90) | 0.025 | ||
Systolic BP (mmHg) | 1.03 (1.02–1.04) | < 0.001 | ||||
Diastolic BP (mmHg) | 0.98 (0.97–1.00) | 0.073 | 0.96 (0.93–1.00) | 0.048 | ||
BMI categories | 1.00 (0.97–1.03) | 0.937 | ||||
Ever smoked | 3.39 (2.32–4.95) | < 0.001 | 2.40 (1.26–4.58) | 0.008 | ||
Albuminuria | 2.30 (1.49–3.56) | < 0.001 | ||||
eGFR (mL/min/1.73 m2) | 0.96 (0.96–0.97) | < 0.001 | ||||
Antihypertensive Rx | 9.74 (6.54–14.49) | < 0.001 | 2.44 (1.15–5.18) | 0.020 | ||
Lipid lowering Rx | 10.13 (6.76–15.17) | < 0.001 | ||||
Retinopathy | 5.07 (3.53–7.28) | < 0.001 | ||||
Stroke | ||||||
Female sex | 0.33 (0.15–0.72) | 0.006 | 0.49 (0.16–1.47) | 0.201 | 0.81 | 0.74–0.88 |
Age (years) | 1.06 (1.04–1.09) | < 0.001 | 1.05 (1.01–1.08) | 0.006 | ||
Diabetes duration group | 1.08 (1.03–1.12) | < 0.001 | ||||
HbA1c (%) | 1.17 (0.99–1.38) | 0.062 | ||||
HDL-cholesterol (mmol/L) | 0.26 (0.09–0.77) | 0.015 | ||||
Systolic BP (mmHg) | 1.02 (1.00–1.04) | 0.016 | ||||
Diastolic BP (mmHg) | 1.00 (0.97–1.04) | 0.928 | ||||
BMI categories | 1.02 (0.96–1.10) | 0.514 | ||||
Ever smoked | 2.32 (1.10–4.92) | 0.027 | ||||
Albuminuria | 2.27 (0.97–5.31) | 0.059 | ||||
eGFR (mL/min/1.73 m2) | 0.97 (0.96–0.99) | < 0.001 | 0.98 (0.96–1.00) | 0.030 | ||
Antihypertensive Rx | 7.85 (3.47–17.74) | < 0.001 | ||||
Lipid lowering Rx | 7.54 (3.35–16.95) | < 0.001 | ||||
Retinopathy | 3.87 (1.88–7.96) | < 0.001 | ||||
Myocardial infarction | ||||||
Female sex | 0.41 (0.23–0.72) | 0.002 | 0.97 (0.39–2.41) | 0.943 | 0.90 | 0.87–0.94 |
Age (years) | 1.08 (1.06–1.10) | < 0.001 | 1.09 (1.05–1.13) | < 0.001 | ||
Diabetes duration group | 1.12 (1.08–1.17) | < 0.001 | ||||
HbA1c (%) | 0.96 (0.82–1.13) | 0.647 | ||||
HDL-cholesterol (mmol/L) | 0.24 (0.10–0.58) | 0.002 | 0.20 (0.06–0.68) | 0.010 | ||
Systolic BP (mmHg) | 1.03 (1.02–1.05) | < 0.001 | ||||
Diastolic BP (mmHg) | 1.01 (0.98–1.03) | 0.707 | ||||
BMI categories | 1.01 (0.95–1.06) | 0.842 | ||||
Ever smoked | 2.31 (1.30–4.10) | 0.004 | ||||
Albuminuria | 2.20 (1.15–4.21) | 0.017 | ||||
eGFR (mL/min/1.73 m2) | 0.97 (0.96–0.98) | < 0.001 | ||||
Antihypertensive Rx | 23.91 (10.12–56.49) | < 0.001 | 5.06 (1.38–18.54) | 0.014 | ||
Lipid lowering Rx | 18.21 (8.14–40.73) | < 0.001 | ||||
Retinopathy | 3.67 (2.12–6.35) | < 0.001 | ||||
Coronary artery bypass graft/angioplasty | ||||||
Female sex | 0.38 (0.22–0.68) | 0.001 | 0.93 (0.34–2.52) | 0.884 | 0.92 | 0.89-0.95 |
Age (years) | 1.09 (1.07–1.12) | < 0.001 | 1.08 (1.03–1.13) | 0.001 | ||
Diabetes duration group | 1.21 (1.13–1.30) | < 0.001 | ||||
HbA1c (%) | 0.96 (0.81–1.12) | 0.586 | ||||
HDL-cholesterol (mmol/L) | 0.27 (0.11–0.67) | 0.005 | 0.23 (0.06–0.92) | 0.038 | ||
Systolic BP (mmHg) | 1.03 (1.01–1.04) | < 0.001 | ||||
Diastolic BP (mmHg) | 0.98 (0.96–1.01) | 0.171 | ||||
BMI categories | 1.03 (0.98–1.09) | 0.263 | ||||
Ever smoked | 2.18 (1.25–3.81) | 0.006 | ||||
Albuminuria | 1.82 (0.93–3.59) | 0.082 | ||||
eGFR (mL/min/1.73 m2) | 0.97 (0.96–0.98) | < 0.001 | ||||
Antihypertensive Rx | 38.63 (13.83–107.88) | < 0.001 | 8.96 (1.12–71.54) | 0.039 | ||
Lipid lowering Rx | 36.00 (12.91–100.41) | < 0.001 | ||||
Retinopathy | 4.45 (2.57–7.69) | < 0.001 | ||||
Peripheral vascular disease | ||||||
Female sex | 0.73 (0.46–1.16) | 0.180 | 1.08 (0.49–2.39) | 0.851 | 0.85 | 0.81–0.90 |
Age (years) | 1.07 (1.05–1.09) | < 0.001 | 1.04 (1.01–1.07) | 0.005 | ||
Diabetes duration group | 1.11 (1.08–1.15) | < 0.001 | ||||
HbA1c (%) | 1.09 (0.96–1.24) | 0.171 | ||||
HDL-cholesterol (mmol/L) | 0.37 (0.18–0.77) | 0.008 | ||||
Systolic BP (mmHg) | 1.02 (1.01–1.04) | < 0.001 | ||||
Diastolic BP (mmHg) | 0.97 (0.95–0.99) | 0.009 | ||||
BMI categories | 0.99 (0.95–1.03) | 0.653 | ||||
Ever smoked | 3.67 (2.22–6.08) | < 0.001 | ||||
Albuminuria | 2.97 (1.65–5.34) | < 0.001 | ||||
eGFR (mL/min/1.73 m2) | 0.96 (0.95–0.97) | < 0.001 | 0.97 (0.96–0.99) | 0.002 | ||
Antihypertensive Rx | 5.26 (3.25–8.53) | < 0.001 | ||||
Lipid lowering Rx | 5.22 (3.21–8.46) | < 0.001 | ||||
Retinopathy | 6.41 (3.95–10.41) | < 0.001 | 2.47 (1.06–5.74) | 0.036 | ||
Congestive cardiac failure | ||||||
Female sex | 1.00 (0.36–2.78) | 0.964 | 1.51 (0.30–7.47) | 0.614 | 0.90 | 0.84–0.95 |
Age (years) | 1.10 (1.06–1.14) | < 0.001 | 1.15 (1.05–1.25) | 0.002 | ||
Diabetes duration group | 1.16 (1.05–1.29) | 0.004 | ||||
HbA1c (%) | 0.97 (0.70–1.34) | 0.858 | ||||
HDL-cholesterol (mmol/L) | 1.68 (0.90–3.16) | 0.104 | ||||
Systolic BP (mmHg) | 1.02 (0.99–1.05) | 0.157 | ||||
Diastolic BP (mmHg) | 0.97 (0.92–1.02) | 0.195 | ||||
BMI categories | 1.20 (1.05–1.38) | 0.008 | ||||
Ever smoked | 1.40 (0.50–3.90) | 0.515 | ||||
Albuminuria | 5.30 (1.36–20.70) | 0.016 | ||||
eGFR (mL/min/1.73 m2) | 0.95 (0.94–0.97) | < 0.001 | ||||
Antihypertensive Rx | 37.42 (4.90–285.81) | < 0.001 | ||||
Lipid Lowering Rx | 6.70 (2.12–21.21) | 0.001 | ||||
Retinopathy | 20.75 (4.65–92.51) | < 0.001 |